Comparison of human insulin and insulin analogues on hypoglycaemia and metabolic variability in type 1 diabetes using standardized measurements (HYPO score and Lability Index)

Acta Diabetologica

Volumn 50, Issue 4, 2013, Pages 529-535

  Perez Maraver M ^a,c,d   Caballero Corchuelo, J ^a,c,d   Boltana, A ^a   Insa, R ^a   Soler, J ^a,b,c,d   Montanya, E ^a,b,c,d  

^a HOSPITAL UNIVERSITARI DE BELLVITGE   (Spain)

^b UNIVERSITY OF BARCELONA   (Spain)

^c BELLVITGE BIOMEDICAL RESEARCH INSTITUTE IDIBELL   (Spain)

^d INSTITUTO DE SALUD CARLOS III   (Spain)

Author keywords

HYPO score; Hypoglycaemia; Insulin analogues; Lability Index

Indexed keywords

GLUCOSE; HEMOGLOBIN A1C; HUMAN INSULIN; INSULIN ASPART; INSULIN DERIVATIVE; INSULIN GLARGINE; ISOPHANE INSULIN; NEUTRAL INSULIN; RECOMBINANT HUMAN INSULIN;

ADULT; ARTICLE; BLOOD GLUCOSE MONITORING; BODY MASS; CLINICAL ARTICLE; CLINICAL EFFECTIVENESS; CONTROLLED STUDY; DRUG EFFECT; DRUG EFFICACY; FEMALE; FOLLOW UP; HUMAN; HYPO SCORE; HYPOGLYCEMIA; INSULIN DEPENDENT DIABETES MELLITUS; LABILITY INDEX; MALE; METABOLIC REGULATION; OUTCOME ASSESSMENT; PRIORITY JOURNAL; PROSPECTIVE STUDY; RANDOMIZED CONTROLLED TRIAL; RISK ASSESSMENT; RISK REDUCTION; SCORING SYSTEM;

ADULT; BLOOD GLUCOSE; DIABETES MELLITUS, TYPE 1; FEMALE; HUMANS; HYPOGLYCEMIA; HYPOGLYCEMIC AGENTS; INSULIN; MALE; MIDDLE AGED; MONITORING, PHYSIOLOGIC; PROSPECTIVE STUDIES; SPAIN; YOUNG ADULT;

EID: 84884903681     PISSN: 09405429     EISSN: 14325233     Source Type: Journal    
DOI: 10.1007/s00592-011-0320-y     Document Type: Article

References (32)

1. The Diabetes Control Complications Trial Research Group (1993) The effect of intensive treatment of diabetes on the development and progression of long-term complications in insulin-dependent diabetes mellitus. N Engl J Med 329:977-986 (Pubitemid 23307905)
2. Kilpatrick ES, Rigby AS, Atkin SL (2008) A1c variability and the risk of microvascular complications in type 1 diabetes. Diabetes Care 31:2198-2202
3. Zafon C, Creus C (2011) A comparison on insulin regimen treatment of elderly (>70 years) and younger (<70 years) type 2 diabetic patients in actual clinical practice. Acta Diabetol. doi: 10.1007/s00592-011-0289-6 (Epub ahead of print)
4. Gentile S, Agrusta M, Guarino G et al (2011) Metabolic consequences of incorrect insulin administration techniques in aging subjects with diabetes. Acta Diabetol 48:121-125
5. Murphy N, Keane S, Ong K et al (2003) Randomized cross-over trial of insulin glargine plus lispro or NPH insulin plus regular human insulin in adolescents with type 1 diabetes on intensive insulin regimens. Diabetes Care 26:799-804 (Pubitemid 36929346)
6. Hirsch IB (2005) Insulin analogues. N Engl J Med 352:174-183 (Pubitemid 40096614)
7. Brunelle RL, Llewelyn J, Anderson J et al (1998) Meta-analysis of the effect of insulin lispro on severe hypoglycemia in patients with type 1 diabetes. Diabetes Care 21:1726-1731 (Pubitemid 28449815)
8. Raskin P, Guthrie R, Leiter L et al (2000) Use of insulin aspart, a fast-acting insulin analog, as the mealtime insulin in the management of patients with type 1 diabetes. Diabetes Care 23:583-588 (Pubitemid 30321534)
9. Chapman TM, Noble S (2002) Insulin aspart: a review of its use in the management of type 1 and 2 diabetes mellitus. Drugs 62:1945-1981
10. Plank J, Siebenhofer A, Berghold A et al (2005) Systematic review and meta-analysis of short-acting insulin analogues in patients with diabetes mellitus. Arch Intern Med 165:1337-1344 (Pubitemid 40973416)
11. Ratner R, Hirsch IB, Neifing JL et al (2000) Less hypoglycaemia with insulin glargine in intensive insulin therapy for type 1 diabetes. Diabetes Care 23:639-643 (Pubitemid 30321544)
12. Hermansen K, Madsbad S, Perrild H et al (2001) Comparison of the soluble basal insulin analog insulin detemir with NPH insulin. Diabetes Care 24:296-301
13. Vague P, Selam JL, Skeie S et al (2003) Insulin detemir is associated with more predictable glycemic control and reduced risk of hypoglycemia than NPH insulin in patients with type 1 diabetes on a basal-bolus regimen with premeal insulin aspart. Diabetes Care 26:590-596 (Pubitemid 36929312)
14. Danne T, Lupke K, Walte K, Von Schuetz W, Gall MA (2003) Insulin detemir is characterized by a consistent pharmacokinetic profile across age-groups in children, adolescent, and adults with type 1 diabetes. Diabetes Care 26:3087-3092 (Pubitemid 37339503)
15. Hasani-Ranjbar S, Fazlollahi MR, Mehri A, Larijani B (2011) Allergy to human insulin and specific immunotherapy with glargine; case report with review of literature. Acta Diabetol. doi: 10.1007/s00592-011-0254-4. [Epub ahead of print]
16. Singh SR, Ahmad F, Lal A, Yu C, Bai Z, Bennett H (2009) Efficacy and safety of insulin analogues for the management of diabetes mellitus: a meta-analysis. CMAJ 180:385-397
17. Gill GV, Yudkin JS, Keen H, Beran D (2011) The insulin dilemma in resource-limited countries. A way forward? Diabetologia 54:19-24
18. Vigneri R, Squatrito S, Sciacca L (2010) Insulin and its analogs: actions via insulin and IGF receptors. Acta Diabetol 47:271-278
19. Sahin SB, Cetinkalp S, Ozgen AG, Saygili F, Yilmaz C (2010) The importance of anti-insulin antibody in patients with type 1 diabetes mellitus treated with continuous subcutaneous insulin infusion or multiple daily insulin injections therapy. Acta Diabetol 47:325-330
20. Ryan EA, Shandro T, Green K et al (2004) Assessment of the severity of hypoglycemia and glycemic lability in type 1 diabetic subjects undergoing islet transplantation. Diabetes 53:955-962 (Pubitemid 38436607)
21. Kapellen TM, Wolf J, Rosenbauer J, Stachow R et al (2009) Changes in the use of analogue insulins in 37,206 children and adolescents with type 1 diabetes in 275 German and Austrian centers during the last twelve years. Exp Clin Endocrinol Diabetes 117:329-335
22. Siebenhofer A, Planck J, Berghold A et al (2006) Short-acting insulin analogues versus regular human insulin in patients with diabetes mellitus. Cochrane Database Syst Rev 2:CD003287
23. Klein O, Lynge J, Endahl L, Damholt B, Nosek L, Heise T (2007) Albumin-bound basal insulin analogues (insulin detemir and NN344): comparable time-action profiles but less variability than insulin glargine in type 2 diabetes. Diabetes Obes Metab 9:290-299 (Pubitemid 46502046)
24. Ashwell SG, Amiel SA, Bilous RW et al (2006) Improved glycaemic control with insulin glargine plus insulin lispro: a multicentre, randomized, cross-over trial in people with type 1 diabetes. Diabet Med 23:285-292
25. Rossetti P, Porcellati F, Bolli G, Fanelli C (2008) Prevention of hypoglycemia while achieving good glycemic control in type 1 diabetes: the role of insulin analogs. Diabetes Care 31(suppl 2):S113-S120
26. Pickup JC, Kidd J, Burmiston S, Yemane N (2006) Determinants of glycaemic control in type 1 diabetes during intensified therapy with multiple daily insulin injections or continuous subcutaneous insulin infusion: importance of blood glucose variability. Diabetes Metab Res Rev 22:232-237 (Pubitemid 43805405)
27. Wentholt IM, Kulik W, Michels RP et al (2008) Glucose fluctuations and activation of oxidative stress in patients with type 1 diabetes. Diabetologia 51:183-190 (Pubitemid 50002199)
28. Ceriello A, Esposito K, Piconi L et al (2008) Oscillating glucose is more deleterious to endothelial function and oxidative stress than mean glucose in normal and type 2 diabetic patients. Diabetes 57:1349-1354
29. Monnier L, Mas E, Ginet C et al (2006) Activation of oxidative stress by acute glucose fluctuations compared with sustained chronic hyperglycemia in patients with type 2 diabetes. JAMA 295:1681-1687
30. Kovatchev BP, Cox DJ, Gonder-Frederick LA, Young-Hyman D, Schlundt D, Clarke W (1998) Assessment of risk for severe hypoglycemia among adults with IDDM: validation of the low blood glucose index. Diabetes Care 21:1870-1875 (Pubitemid 28478285)
31. Clarke W, Cox DJ, Gonder-Frederick LA, Julian D, Schlundt D, Polonsky W (1995) Reduced awareness of hypoglycemia in adults with IDDM: a prospective study of hypoglycemic frequency and associated symptoms. Diabetes Care 18:517-522
32. Service FJ, Molnar GD, Rosewear JW et al (1970) Mean amplitude of glycemic excursions, a measure of diabetic instability. Diabetes 19:644-655